Kalshi’s dozen drug-trial markets draw senate scrutiny

Researchers warned in October that market odds could sway trial participant behaviour & public trust.

The hit

Democratic senators Angela Alsobrooks & Ron Wyden have sent HHS a letter demanding to know what safeguards exist for betting markets tied to clinical trials & FDA decisions, according to CNBC, which first obtained the letter. The demand targets Kalshi’s pilot, launched in July 2026, covering roughly a dozen FDA-related contracts.

Why it matters

For traders, the letter raises the question of whether HHS or another regulator eventually restricts or shuts down drug-trial contracts. Unlike elections, trial outcomes sit with a small circle of insiders, not millions of voters, which is why researchers worry odds could sway participant behaviour & public trust in results.

The record

Pilot launch	July 2026 (Kalshi)
Contracts covered	roughly a dozen FDA-related event contracts (Kalshi)
Researcher warning	October 2026, Boston University & other institutions flag risks to trial integrity
Public Citizen rebuke	named clinical trial betting its ‘Outrage of the Month’ on 2 November 2026
HHS response	none publicly issued as of early November 2026

What happens next

Watch for whether HHS answers the senators publicly, whether Kalshi expands or trims its FDA-related slate, & whether trading volume data for the drug contracts ever surfaces.

Sources: Senators press HHS on prediction markets tied to drug trials

Named in this story? Reply to newsdesk@pollbet.com & we publish it.

18+. Betting involves risk. If gambling is a problem for you or someone close to you, help is available.